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Abstract 
Background: A malaria slide bank (MSB) is a useful asset for any malaria microscopy testing laboratory to have access 
to. However, it is not feasible for every country to have its own MSB. If countries are able to pool their resources, a 
regional MSB is a viable solution. This paper describes the methodology, costing and lessons learnt of establishing 
and maintaining an MSB over a 3-year period, for a Southern Africa Development Community region.
Methods: A national reference laboratory in South Africa was granted funding for setting up the MSB; it possessed 
experienced staff and suitable resources. Two additional full-time personnel were employed to carry out the activities 
of this project. Strict protocols for donor/patient blood sample screening, smear preparation, mass staining, quality 
control and slide validation were followed. Slides from the MSB were used for training and proficiency testing pur-
poses. The initial and recurrent yearly costs to set up and maintain the MSB were calculated.
Results: Over 35 months, 154 batches (26,623 slides) were prepared; the majority were Plasmodium falciparum. 
Ninety-two percent (141/154) of batches passed internal quality control, and 89% (93/104) passed external validation. 
From these slides, two training slide sets and six proficiency testing slide sets were sent out. The initial year’s cost to 
establish an MSB was calculated at approximately $165,000, and the recurrent year-on-year cost was $130,000.
Conclusions: The key components for maintaining a high-quality MSB are consistent funding, competent staff and 
adherence to standardized protocols. Travel to malaria-endemic areas for access to non-falciparum malaria species, 
and dilution of P. falciparum blood to desired parasite densities, are extremely useful to ensure variety. The MSB cre-
ated here supported multiple laboratories in eight countries, and has the potential to expand.
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Background
Population mobility across borders, where it involves 
movement of malaria parasite-infected people, poses 
challenges to countries’ efforts to achieve malaria elimi-
nation [1–3]. Joint cross-border efforts form a key part 
of the framework to eliminate malaria from endemic 
regions worldwide [2, 4]. The Southern Africa Develop-
ment Community (SADC) Malaria Elimination Eight 
(E8) was established by SADC heads of state in 2009, to 
coordinate and execute regional strategies with the aim 
of eliminating malaria by 2030 [2]. The eight countries 
are Angola, Botswana, Eswatini, Mozambique, Namibia, 
South Africa, Zambia and Zimbabwe.
Universal access to malaria diagnosis is part of the 
World Health Organization (WHO) strategic frame-
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[5, 6]. Quality-assured diagnosis, either microscopy or 
rapid diagnostic tests (RDTs), is recommended before 
treatment is administered to patients and is an essential 
requirement for the certification of malaria-free status 
by the WHO [6]. In 2017, the E8, through a grant from 
the Global Fund against Aids, Tuberculosis and Malaria, 
and with support from the WHO Regional Office for 
Africa (AFRO), initiated activities that were designed 
to build and strengthen high-quality diagnostic capac-
ity in the region. These were: (1) the development of a 
regional malaria slide bank (MSB); (2) the formal assess-
ment of core microscopists; and (3) the training of core 
microscopists to become proficient malaria micros-
copy trainers. These activities are part of the WHO’s 10 
key components of a quality assurance (QA) system in 
malaria microscopy diagnosis [7].
A collection of well-characterized, good quality blood 
films is an indispensable asset to a malaria QA sys-
tem. The objectives of an MSB are to provide sets of 
known, replicate slides for training, external and internal 
assessment of microscopists, and for proficiency test-
ing schemes (PTS). The provision of such a resource at 
regional level is likely to be highly cost-effective com-
pared to duplication of such facilities in each country. 
Furthermore, most countries lack the infrastructure, 
expertise and resources to establish an MSB.
This paper details the process and cost of setting-up 
and maintaining a regional MSB. In 2018, the National 
Institute for Communicable Diseases (NICD) was 
awarded an E8-administered grant to establish an MSB. 
The NICD is a division of the South African Depart-
ment of Health’s National Health Laboratory Service, 
and provides reference diagnostic laboratory services for 
the country and region, as well as training and research 
functions for communicable diseases of public health 
importance [8]. As such, the NICD performs the role of 
a national malaria reference laboratory. The NICD main-
tains ISO 15189 accreditation and was also previously 
ISO 17043-accredited in its role as an EQA provider.
Methods
The WHO Malaria Microscopy QA Manual (Chapter 12) 
was used for guidance on the requirements of an MSB 
and the steps involved to develop it [7]. Using this man-
ual, in addition to its own experience and procedures, the 
NICD went about developing an MSB for the E8 region. 
In May 2018, the NICD employed two medical technolo-
gists who were dedicated to this project, following thor-
ough internal training on all processes. They attended 
an MSB training workshop organized and funded by 
the WHO AFRO in August 2018. Among the facilita-
tors were staff from the Research Institute for Tropical 
Medicine (RITM), Philippines. The RITM has the only 
WHO-approved MSB in the world and graciously shared 
its methods. See Additional file  1 for details of staff 
training.
The aim was to prepare 50 batches of at least 100 slides 
each in year 1, and 100 batches each in year 2 and 3. Here, 
a batch is defined as all replicate slides prepared together 
from the same blood tube. An MSB ideally should acquire 
blood smears of all human species of Plasmodium and 
malaria-negative smears, as well as non-malaria parasites 
such as trypanosomes and microfilariae. Slide prepara-
tion began immediately after staff were employed and 
trained. As the NICD is not a routine testing facility, 
nearby routine diagnostic laboratories around Johan-
nesburg (see Additional file  2) were requested to kindly 
notify the NICD when they had a positive malaria sam-
ple. After the EDTA blood sample was used for diagnos-
tic purposes, the residual sample, usually between 1 and 
4 ml, was fetched. Malaria-negative blood was collected 
from healthy staff who volunteered to donate 4–8  ml 
of their blood. Ethical clearance was obtained from the 
University of Witwatersrand Human Research Ethics 
Committee (clearance certificate number M161061) for 
the use of samples collected from patients with parasitic 
infections, and the collection of samples from healthy 
donors for MSB purposes.
The quality of samples was assessed by microscopi-
cally examining the parasites and blood components. 
If acceptable, mass blood smear preparation was car-
ried out. Smears were left to dry for at least 24  h, after 
which thin films were fixed with 100% methanol (Merck 
KGaA, 64271 Darmstadt, Germany). Mass staining was 
performed for 30 min with a 3% Giemsa solution (Merck 
KGaA, 64271 Darmstadt, Germany), prepared with a 
phosphate buffer of pH 7.2 (Diagnostic Media Products, 
Johannesburg, South Africa). Desired parasite densities 
(parasitaemias) were produced by diluting positive blood 
with healthy donor blood of the same ABO blood group. 
After staining, slides underwent internal quality control 
(QC), whereby slides were macroscopically and micro-
scopically examined, and parasite counts were performed 
on all malaria-positive slides [9]. Poor quality slides 
failed QC and were discarded. Slides from batches that 
passed QC were sent to WHO-certified level 1 micros-
copists from within the E8 region, for validation. Batches 
that passed validation were added to the MSB inventory. 
For long-term storage, slides were coverslipped using 
an automated coverslipping instrument (Leica CV5030, 
Leica Biosystems, Buffalo Grove, IL 60089 United States) 
and labelled before being stored in slide cabinets. A real-
time PCR assay using a commercial kit (RealStar Malaria 
Screen & Type PCR Kit 1.0, Altona Diagnostics, Ham-
burg, Germany; QuantStudio 5 Real-Time PCR System, 
ThermoFisher Scientific, Walham, MA USA 02451) 
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was performed on every blood sample used to prepare 
smears, to confirm the microscopic species identification. 
Using the validators’ microscopy results and the PCR 
results a consensus malaria species identification was 
made. Detailed methodology and illustrative images are 
provided in Additional files 3 and 4, respectively.
In September 2018, in an effort to increase the stock 
of non-falciparum slides, staff travelled to a malaria-
endemic town in Kenya. For a week, they prepared blood 
smears from malaria-positive blood samples collected 
at two malaria testing sites. Smears were prepared using 
the same process detailed above, except that after smears 
dried, slides were immediately packaged and airfreighted 
on ice to the NICD the following morning. Slides were 
received within 24  h of production and were stained 
within 2–4 days.
The cost of setting-up an MSB was calculated using 
2020 cost estimates. The year 1 or initial costs included 
the once-off costs of equipment purchases and installa-
tion, as well as the cost of preparing 50 slide batches (of 
100 slides each). The recurrent year-on-year costs of the 
MSB included the costs of equipment maintenance and 
preparation of 100 slide batches. The cost of two, 2-week 
field trips a year, to recruit patients and prepare smears, 
was included in the annual budget.
From this MSB, slide sets were assembled and shipped 
by airfreight to participating laboratories for microsco-
pist training and for a proficiency testing scheme (PTS). 
Registration of laboratories in the PTS was first approved 
by WHO/E8. The PTS was designed using the guide-
lines provided in the WHO Malaria Microscopy QA 
Manual, Chapter  11 [7]. For both the training and PTS 
activities, slides were selected from the slide storage cabi-
nets, re-labelled, packed into slide boxes, and shipped. 
A questionnaire was administered to PTS participants 
in December 2020 for monitoring and improvement 
purposes.
Results
Figure 1 is a summary of the 154 batches (26,623 slides) 
prepared from May 2018 to March 2021. The month 
with the highest number of slides made was September 
2018, in which 14 batches were prepared in Kenya; this 
included five non-falciparum malaria and mixed species 
infections. There were 67 batches prepared in 2018, 44 in 
2019, 24 in 2020 and 19 in 2021. The average batch size 
was 170 (range: 20–392). The majority of slide batches 
was Plasmodium falciparum (64%), followed by malaria-
negative (16%), non-malaria (10%) and non-falciparum 
















































































































































































Fig. 1 Timeline showing number of slide batches (bars) and cumulative number of slides (line) prepared for the NICD/E8 Malaria Slide Bank, 
January 2018–March 2021
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batches were prepared from clinical samples diluted with 
donor blood.
Ninety-two percent (141/154) of batches passed inter-
nal QC. Of these, 104 (84%) were sent for validation to 
level 1 microscopists in Zambia, Botswana and Mozam-
bique. Eighty-nine percent (93/104) passed this exter-
nal validation and these batches were added to the MSB 
stock. Of these, 72 were malaria-positive batches which 
were all counted by the validators. The median count of 
the validators’ counts was used as the true count for each 
batch; true counts ranged between 48 and 240,486 p/µl. 
The true counts were assigned to arbitrary categories; 
25% (18/72) were considered low counts (< 300 p/µl), 24% 
(17/72) medium counts (300–999 p/µl) and 51% (37/72) 
high counts (≥ 1,000 p/µl). PCR results were concordant 
with the validated microscopy results for all production 
batches. There were four samples that had an additional 
species-positive PCR result with a very high Ct value 
(indicating submicroscopic infections) that did not match 
microscopy results and these were excluded.
The initial cost of establishing an MSB was calculated 
at roughly $165,000, using the Rand/Dollar exchange 
rate on 30 June 2020 (17.28); see Additional file  5. The 
recurrent year-on-year costs were roughly $130,000, 
or $16,000 per E8 country. The main cost drivers in the 
recurrent costs were travel and staff. The following pro-
ject-specific requirements were excluded from costing: 
(1) existing staff time, estimated as 0.20 × full time equiv-
alent in the first year; (2) malaria microscopy training 
and ECAMM workshop attendance (E8 sponsored); (3) 
an air-conditioned room with benches, cupboards and 
shelves; (4) safety consumables such as PPE and waste 
containers, and (5) basic stationery.
From this slide bank, in 2019–2020, two training slide 
sets were sent to each country’s malaria reference labo-
ratory, and five malaria microscopy proficiency testing 
scheme (PTS) surveys were sent to 12–14 participating 
laboratories. There was a 79% (11/14) response rate to 
the PTS participant feedback questionnaire. Of the labo-
ratories that responded, the majority (73%, 8/11) did not 
participate in any other malaria microscopy PT/EQA. All 
11 respondents were satisfied with the PT service and 
rated the quality of the blood films an average score of 
4.5 out of 5. The online submission process was rated an 
average score of 4.4 out of 5, but some technical difficul-
ties with the online system were noted. Suggestions for 
improvement were to start the programme earlier in the 
year and to include Plasmodium vivax slides.
Discussion
This MSB is one of the key initiatives in the E8 Regional 
Malaria Diagnosis Programme that aims to provide 
regional support to help develop robust quality assurance 
programmes to improve the performance and quality of 
malaria diagnostic services provided within the region. 
Here, it was shown that with adequate funding, well-
trained staff and clear protocols, setting up an MSB is 
an achievable task. In 35 months, 154 batches were pre-
pared; although this was fewer than planned, the total 
number of slides prepared was on target. There were also 
far fewer batches of non-falciparum malaria smears than 
anticipated. A major contributing reason for the reduced 
number of batches, particularly non-falciparum smears, 
was the COVID-19 pandemic that resulted in a decrease 
in local malaria cases being identified, and the cancella-
tion of the second field trip to a highly malaria-endemic 
country.
There were many lessons learned during the develop-
ment of this MSB, which may be instructive for other 
groups. One of the limitations of the residual positive-
blood sample acquisition process was that many blood 
samples were not received within 6  h of collection, but 
more usually within 24  h. While in principle, blood 
smears should be prepared as quickly as possible follow-
ing venepuncture to ensure optimal parasite morphology 
and staining [7, 10], some older samples may be used suc-
cessfully. To nevertheless maintain a high standard, the 
quality of the parasite and blood component morphology 
and staining was checked before mass smear preparation. 
The majority of samples remained acceptable within this 
time-frame. Of interest was that trypanosomes survived 
in EDTA-blood for a few days and, therefore, their mor-
phology was maintained for longer than malaria para-
sites. Lastly, all MSB slides were independently validated 
by unbiased level 1-certified microscopists, which further 
confirms the acceptability of these smears. A second lim-
itation of the sample collection procedure used, was that 
there was no control over the volume of blood received in 
the samples, hence the large range of batch sizes in this 
MSB. These blood samples were collected for diagnostic 
purposes and residual post-testing blood was used for the 
MSB. It is preferable to actively and immediately collect 
EDTA-blood and prepare smears on site from patients 
who test positive for malaria, as was done during the 
slide preparation in Kenya.
Smear uniformity within batches is very important for 
an MSB, as the slides should be interchangeable. The use 
of slide templates, measuring pipettes and regular blood 
sample mixing during slide preparation assists with 
homogeneity. Slide validation is a key component in the 
MSB process, as it provides multiple, independent, and 
unbiased expert reviews of the smears. The E8 sponsored 
the attendance of core microscopists from E8 countries 
in External Competence Assessment in Malaria Micros-
copy (ECAMM) workshops, and as a result the NICD 
were able to request, in return, the voluntary support of 
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level 1 microscopists for slide validation. Initially, inad-
vertent collusion between microscopists was noted, and 
therefore not all the validation results were used. This 
issue was resolved with communication and revised 
instructions indicating that slide validation must be per-
formed independently. PCR was most useful in cases of 
relapsing malaria species, where microscopic identifica-
tion was often difficult. PCR results that indicated very 
scanty infections (high Ct values) that were not detected 
by microscopy were excluded from the composite diag-
nosis, as done by others [10].
When fixing blood films in methanol, it is best to use 
‘fresh’ methanol. Due to the hydrophilic nature of this 
chemical, it becomes gradually diluted when exposed to 
air moisture, thereby losing its fixative efficacy. To over-
come this, it was found that aliquotting methanol from 
a new container into smaller bottles kept the methanol 
effective. These bottles should be filled to capacity, kept 
tightly capped until used, and labelled with safety and lot 
details. When planning for smear preparation in Kenya, 
it became evident that it would be preferable to perform 
staining in South Africa. The concern was to prevent fix-
ation of thick smears due to exposure to high humidity 
and heat before staining. To overcome this, smears were 
packed on ice and airfreighted to South Africa within 
24 h of preparation. Smears were initially stained within 
2 days of preparation but condensation on the slides from 
the shipping conditions (despite desiccant) resulted in 
this being extended to 3–4 days.
The biggest challenge experienced when developing the 
MSB was obtaining the less common malaria species; a 
field trip to a high-burden country was extremely ben-
eficial in this regard. An alternative is to purchase slides 
from other, well-established slide banks. However, the 
quality of these slides will need to be thoroughly assessed 
before being accepted. To increase the diversity of the P. 
falciparum stock in the MSB, dilution to desired para-
sitaemias is very worthwhile. When diluting blood to 
obtain lower parasitaemias, it is best to use donor blood 
of the same ABO blood group to prevent erythrocyte 
clumping. The inclusion of some non-malaria parasites 
is good as microscopists should be aware of other path-
ogens that they may observe when performing malaria 
microscopy [11].
Based on the costing shown, the initial costs of set-
ting-up an MSB are substantially reduced if an existing 
malaria laboratory with the basic equipment, consuma-
bles and reagents is used. The estimated minimum 
funding required for annual maintenance of the MSB 
is reasonable, especially as it is able to serve multiple 
countries in a region. The largest cost components are 
travel and staff salaries. The costs here were calculated 
on the quantity of the items needed to prepare 100 slide 
batches per year. However, many items are only sold in 
larger quantities, which will inflate the actual initial cost 
but also reduce recurrent year-on-year costs. Consistent 
internal quality control of smears pre- and post-staining 
avoids the unnecessary cost of shipping poor-quality 
batches for validation. As mentioned, the cost of slide 
validation was reduced due to the E8 sponsoring the level 
1 microscopists attendance at the ECAMM workshops. 
There are other options to cut costs, for example the 
use of bottled drinking water to dilute the Giemsa stain 
[12], or the use of a cheaper molecular assay for species 
confirmation.
As well as producing slides for microscopist training, 
an MSB can supply proficiency testing schemes. There 
is a demand for malaria microscopy PT schemes that 
comprehensively assess species identification and para-
site quantitation. The overall good feedback from par-
ticipants endorses the quality of this MSB and PTS. In 
addition to supplying slides for training and PTS, an MSB 
may loan or sell slides. It is the intention of this MSB to 
offer these services, but it is dependent on the growth of 
the slide bank. Additionally, if this MSB grows substan-
tially the slides and the NICD/E8 Malaria Microscopy PT 
Scheme has the potential to support countries outside of 
the E8. There has been a large number of requests to join 
this PTS from health institutions in countries within the 
E8, such as Botswana, Zimbabwe and Eswatini, and from 
outside the region, such as The Gambia, Kenya, Tanzania 
and Rwanda.
An excellent MSB has first-rate, validated smears 
i.e., uniform macroscopic and microscopic appearance 
and good quality staining. There are very few published 
accounts of MSBs [10, 13]. However, from personal com-
munications, there are some countries that have started 
their own MSBs. The limitations of these MSBs may 
include varying quality, limited species, and un-validated 
smears that may mislead microscopists. It is not feasible 
for every country to develop its own MSB, especially due 
to lack of resources and more importantly, limited access 
to positive blood samples. For this reason, it is preferable 
to develop a regional slide bank as described here that 
can support multiple countries.
Conclusions
Malaria specimen banks in general are in demand, espe-
cially in Africa. Such banks can provide various spe-
cies and strains of malaria in different forms including 
microscopy slides, dried blood spots, RDT controls and 
parasite DNA. This MSB has proven to be an essential 
tool in the region as it moves towards malaria elimina-
tion. The E8 participating laboratories have become 
dependent on this MSB especially as for many of them, 
it is the only source of PTS material. Unfortunately, the 
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grant funding for this project was limited and unless fur-
ther funding is acquired, this valuable resource will cease 
to exist.
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